Liver Resection After Atezo–Bev Improves Disease Control in Selected Advanced HCC (TALENTOP Trial): The Lancet | August 2026

Introduction:

Systemic therapy has traditionally been the mainstay for HCC with macrovascular invasion. However, increasingly effective immunotherapy-based regimens can produce substantial tumor regression, raising an important question: should selected responders subsequently undergo curative-intent liver resection rather than simply continue systemic therapy?

The phase III TALENTOP trial provides randomized evidence addressing this conversion-surgery strategy after atezolizumab–bevacizumab (Atezo–Bev).

Why was this study needed?

Conversion surgery after systemic therapy is increasingly performed, but evidence has largely been retrospective.

Atezo–Bev can downstage or stabilize locally advanced HCC.

Whether removing residual disease after systemic response improves outcomes was unknown.

Randomized evidence was needed before incorporating surgery into this treatment pathway.

Results:

489 patients with macrovascular invasion and no extrahepatic metastases received Atezo–Bev–based induction; 201 responders with technically resectable disease were subsequently randomized.

Liver resection followed by Atezo–Bev significantly prolonged median time to treatment failure: 20.4 vs 11.8 months with maintenance therapy (HR 0.60).

This represents approximately a 40% reduction in treatment-failure risk with the surgery-based strategy.

Grade 3–4 treatment-related adverse events were higher with surgery (39% vs 21%), and two treatment-related deaths occurred in the surgical group.

Clinical Impact:

TALENTOP provides important randomized support for a conversion-treatment paradigm in advanced HCC:

Atezo–Bev induction → assess biological response and technical resectability → liver resection in carefully selected responders → postoperative systemic therapy.

The finding challenges the traditional assumption that macrovascular invasion automatically commits a patient to indefinite systemic treatment.

However, this is a highly selected population: patients had no extrahepatic metastases, demonstrated disease control after induction, and were considered technically resectable. The primary endpoint was time to treatment failure—not overall survival—and surgery introduced additional morbidity and mortality.

Bottom Line:

In carefully selected HCC patients with macrovascular invasion who respond to Atezo–Bev and become resectable, conversion liver resection significantly prolonged treatment-failure–free survival compared with continuing systemic therapy alone. TALENTOP provides phase III evidence that systemic therapy in advanced HCC can, for selected patients, become a bridge to potentially definitive surgery rather than the final treatment destination.